Aspire Biopharma Warrant
ASBPW
36 hedge funds and large institutions have $7.27M invested in Aspire Biopharma Warrant in 2022 Q2 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$228K |
| 2 |
SCM
Saba Capital Management
New York
|
+$214K |
| 3 |
LA
Linden Advisors
New York
|
+$196K |
| 4 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$146K |
| 5 |
SC
Sculptor Capital
New York
|
+$109K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KL
26
KIM LLC
Wichita,
Kansas
| $12K | +$21.8K | +100,000 | New |
|
|
WAM
27
Weiss Asset Management
Boston,
Massachusetts
| $8K | +$14.4K | +66,199 | New |
|
|
KKRC
28
Kohlberg Kravis Roberts & Co
New York
| $6K | +$8.16K | +37,500 | New |
|
|
PCM
29
Prelude Capital Management
New York
| $4K | +$5.13K | +23,571 | New |
|
|
MTCM
30
Mint Tower Capital Management
Amsterdam,
Netherlands
| $4K | +$5.44K | +25,000 | New |
|
31
UBS Group
Zurich,
Switzerland
| $4K | +$5.44K | +25,000 | New |
|
|
CM
32
Cohanzick Management
Pleasantville,
New York
| $3K | +$4K | +18,383 | New |
|
|
CH
33
CVI Holdings
Wilmington,
Delaware
| $3K | +$5.44K | +25,000 | New |
|
|
PI
34
PEAK6 Investments
Chicago,
Illinois
| $2.63K | +$5.44K | +25,000 | New |
|
|
CS
35
Clear Street
New York
| $2K | +$3.01K | +13,821 | New |
|
|
MF
36
Magnetar Financial
Evanston,
Illinois
| $3 | +$4.4K | +20,250 | New |
|
|
IRC
37
Investors Research Corp
Atlanta,
Georgia
| – | +$2 | +10 | New |
|
ASBPW Hedge Fund Activity: Q2 2022 in Review
36 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q2 2022, worth a combined $7.27M.
Buyers outnumbered sellers: 36 funds opened new ASBPW positions and 0 closed out — a net gain of 36 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $228K.
- 36 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q2 2022, up from 0 in Q1 2022.
- Funds reported $7.27M of Aspire Biopharma Warrant stock for Q2 2022.
- 36 funds opened new Aspire Biopharma Warrant positions in Q2 2022 and 0 closed out, a net change of +36 holders.
- The largest Aspire Biopharma Warrant buyer in Q2 2022 was Adage Capital Partners, an estimated $228K added.
Based on aggregated 13F filings for Q2 2022.